The management of multiple sclerosis in children: A European view

Multiple Sclerosis

Volumn 16, Issue 10, 2010, Pages 1258-1267

  Ghezzi, Angelo ^a   Banwell, Brenda ^b   Boyko, Alexey ^c   Amato, Maria Pia ^d   Anlar, Banu ^e   Blinkenberg, Morten ^f   Boon, Maartje ^g   Filippi, Massimo ^h   Jozwiak, Sergiusz ⁱ   Ketelslegers, Immy ^j   Kornek, Barbara ^k   Ming Lim, ^l   Lindstrom, Eva ^m   Nadj, Congor ⁿ   Neuteboom, Rinze ^j   Rocca, Maria A ^h   Rostasy, Kevin ^o   Tardieu, Marc ^p   Wassmer, Evangeline ^q   Catsman Berrevoets, Coriene ^j   Hintzen, Rogier ^j   more..

^a Centro Studi SM   (Italy)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^d UNIVERSITY OF FLORENCE   (Italy)

^e HACETTEPE UNIVERSITY   (Turkey)

^f Rigshospitalet   (Denmark)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

ⁱ CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k MEDICAL UNIVERSITY OF VIENNA   (Austria)

^l ST THOMAS HOSPITAL   (United Kingdom)

^m KAROLINSKA INSTITUTE   (Sweden)

ⁿ Institute of Neurology   (Serbia)

^o INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^p BICÊTRE HOSPITAL   (France)

^q BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

more..

Author keywords

children; clinically isolated syndrome; immunomodulatory treatment; MRI; MS; paediatric

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FINGOLIMOD; GADOLINIUM; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; LAQUINIMOD; MITOXANTRONE; NATALIZUMAB; RITUXIMAB;

ADOLESCENT; ADULT; ALOPECIA; AMENORRHEA; ARTHRALGIA; ARTHRITIS; BLADDER CANCER; BLOOD CELL COUNT; CANADA; CANCER RISK; CARDIOMYOPATHY; CHILD; CLINICAL PRACTICE; COGNITIVE DEFECT; CONTRAST ENHANCEMENT; DEPRESSION; DISEASE COURSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEADACHE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION RISK; INFERTILITY; INJECTION SITE ABSCESS; INJECTION SITE REACTION; LEUKEMIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MELANOMA; MENTAL DISEASE; MORBIDITY; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OSTEOPOROSIS; PHYSICAL DISABILITY; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECURRENCE RISK; RELAPSE; REMISSION; REVIEW; SIDE EFFECT; SUICIDE ATTEMPT; THORAX PAIN; THYROID DISEASE; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; AGE OF ONSET; CHILD; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PATIENT CARE TEAM; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; TREATMENT FAILURE;

EID: 77957556137     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510375568     Document Type: Review

References (68)

1. Banwell B., Ghezzi A. and Bar-Orr A. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol 2007 ; 6: 887-902.
2. Ghezzi A., Pozzilli C., Liguori M., et al. Prospective study of multiple sclerosis with early onset. Mult Scler 2002 ; 8: 115-118.
3. Renoux C., Vukusic S., Mikaeloff Y., et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007 ; 365: 2603-2613.
4. Gusev E., Boiko A., Bikova O., et al. The natural history of early onset multiple sclerosis: comparison of data from Moscow and Vancouver. Clin Neurol Neurosurg 2002 ; 104: 203-207.
5. Gorman MP, Healy BC, Polgar-Turcsanyi M. and Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 2009 ; 66: 54-59.
6. Boiko A., Vorobeychik G., Paty D., et al. Early onset multiple sclerosis: a longitudinal study. Neurology 2002 ; 59: 1006-1010.
7. Banwell BL and Anderson PE The cognitive burden of multiple sclerosis in children. Neurology 2005 ; 64: 891-894.
8. MacAllister WS, Belman AL, Milazzo M., et al. Cognitive functioning in children and adolescents with multiple sclerosis. Neurology 2005 ; 64: 1422-1425.
9. Amato M., Goretti B., Ghezzi A., et al. Cognitive and psychosocial features of childhood and juvenile MS. Neurology 2008 ; 70: 1891-1897.
10. Fisher JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon-beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000 ; 48: 885-892.
11. Kappos L., Freedman M., Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009 ; 11: 987-997.
12. Goodin DS, Frohman EM, Garmany GP, et al. Disease-modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002 ; 58: 169-178.
13. Banwell B. Treatment of children and adolescents with multiple sclerosis. Expert Rev Neurother 2005 ; 5: 391-401. (Pubitemid 40705281)
14. Ghezzi A. Childhood-juvenile multiple sclerosis: clinical characteristics and treatment. Expert Rev Neurother 2005 ; 5: 403-411.
15. Pohl D., Waubant E., Banwell B., et al. Treatment of pediatric multiple sclerosis and variants. Neurology 2007 ; 68 (Suppl 2). S54 - S65.
16. Elovaara I., Apostolski S., van Doorn P., et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological disorders. Eur J Neurol 2008 ; 15: 893-908.
17. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999 ; 46: 878-886.
18. Takahashi I., Sawaishi Y., Takeda O., et al. Childhood multiple sclerosis treated with plasmapheresis. Pediatr Neurol 1997 ; 17: 83-87.
19. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I clinical results of a multicenter, randomised, double-blind, placebo-controlled trial. Neurology 1993 ; 43: 655-661.
20. The IFNB Multiple Sclerosis Study Group and the UBC MS/MRI Analysis Group. Interferon beta-1b in the treatment of MS: final outcome of the randomised controlled trial. Neurology 1995 ; 53: 1277-1285.
21. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta 1-a for disease progression in exacerbating-remitting multiple sclerosis. Ann Neurol 1996 ; 39: 285-294.
22. PRISM Study Group. Randomized double-blind placebo-controlled study of interferon beta 1-a in relapsing-remitting multiple sclerosis. Lancet 1998 ; 352: 1498-1504.
23. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995 ; 45: 1268-1276.
24. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000 ; 343: 898-904.
25. Comi G., Filippi M., Barkhof F., et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001 ; 357: 1576-1582.
26. Kappos L., Polman C., Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006 ; 67: 1242-1249.
27. Comi G., Martinelli V., Rodegher M., et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009 ; 374: 1503-1511.
28. Kappos L., Freedman MS, Polman C., et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis. Lancet Neurol 2007 ; 370: 389-397.
29. Filippi M., Rovaris M., Inglese M., et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004 ; 364: 1489-1496.
30. Soriani MP, Bonzano L., Roccatagliata L., et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis. A meta-analytic approach. Ann Neurol 2009 ; 65: 268-275.
31. Waubant E., Hietpas J., Stewart T., et al. Interferon beta-1a in children with multiple sclerosis is well tolerated. Neuropediatrics 2001 ; 32: 211-213.
32. Mikaeloff Y., Moreau T., Debouverie M., et al. Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J Pediatr 2001 ; 139: 443-446.
33. Kornek B., Bernert G., Balassy C., et al. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics 2003 ; 34: 120-126.
34. Pohl D., Rostasy K., Gartner J. and Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology 2005 ; 65: 888-890.
35. Ghezzi A., Amato MP, Gallo P., et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of the ITEMS (immunomodulatory treatment of early-onset MS) study group. Mult Scler 2005 ; 11: 420-424.
36. Pakdaman H., Fallah A., Sahraian MA, et al. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a. Neuropediatrics 2006 ; 37: 257-260.
37. Banwell B., Reder AT, Krupp L., et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 2006 ; 66: 472-476.
38. Tenembaum SN and Segura MJ Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology 2006 ; 67: 511-513.
39. Mikaeloff Y., Caridde G., Tardieu M., et al. Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative study. Eur J Paediatr Neurol 2008 ; 12: 205-209.
40. Ghezzi A., Amato MP, Annovazzi P., et al. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurol Sci 2009 ; 30: 193-199.
41. Trojano M., Pellegrini F., Paolicelli D., et al. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol 2009 ; 66: 513-520.
42. Rio J., Nos C., Tintor M., et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006 ; 59: 344-352.
43. Portaccio E., Zipoli V., Siracusa G., et al. Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria. Mult Scler 2006 ; 12: 281-286.
44. Freedman MS, Patry DG, Grand?Maison F., et al. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004 ; 31: 157-168.
45. Rio J., Rovira A., Tintor M., et al. Relationship between MRI lesion activity and response to IFN-2 in relapsing- remitting multiple sclerosis patients. Mult Scler 2008 ; 14: 479-484.
46. Rio J., Castello J., Tintor M., et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 2009 ; 15: 848-853.
47. Rudick R., Lee J., Simon J., et al. Defining interferon ?2 response status in multiple sclerosis. Ann Neurol 2004 ; 56: 548-555.
48. Tomassini V., Paolillo A., Russo P., et al. Predictors of long-term clinical response to interferon ?2 therapy in relapsing multiple sclerosis. J Neurol 2006 ; 253: 287-293.
49. Malucchi S., Gilli F., Caldano M., et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008 ; 70: 1119-1127.
50. Farrell R., Karoo R. and Leary S. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of interferon-beta. Mult Scler 2008 ; 14: 212-218.
51. Srensen PS, Deisenhammer F., Duda P., et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005 ; 12: 817-827.
52. Srensen PS, Tscherning T., Mathiesen HK, et al. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology 2006 ; 67: 1681-1683.
53. Kappos L., Clanet M., Sandberg-Wollheim M., et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005 ; 65: 40-47.
54. Capobianco M., Rizzo A., Malucchi S., et al. Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients. Neurol Sci 2008 ; 29: S227 - S229.
55. Polman CH, O'Connor PW, Havrdova E., et al. A randomized, placebo-controlled trial of Natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 ; 354: 899-910.
56. Havrdova E., Galetta S., Hutchinson M., et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing- Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009 ; 8: 254-260.
57. Yousry TA, Major EO, Ryschkewitsch C., et al. Evaluation of patients treated with natalizumab for Progressive Multifocal Leukoencephalopathy. N Engl J Med 2006 ; 354: 924-933.
58. Kappos L., Bates D., Hartung HP, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007 ; 6: 431-434.
59. Boriello G., Prosperino L., Lucchetti A. and Pozzilli C. Natalizumab treatment in pediatric multiple sclerosis: a case report. Eur J Paediatr Neurol 2009 ; 13: 67-71.
60. Huppke P., Stark W., Zurcher C., et al. Natalizumab use in pediatric multiple sclerosis. Arch Neurol 2008 ; 65: 1655-1658.
61. Ghezzi A., Pozzilli C., Brescia-Morra V., et al. Safety and effectiveness of natalizumab in paediatric multiple sclerosis: results of 17 patients. Mult Scler 2009 ; 15 (Supp 19). Abstracts MS Variants S151 - S269, Poster 774.
62. Ellis R. and Boggild M. Therapy related acute leukaemia with mitoxantrone: what is the risk and can we minimise it? Mult Scler 2009 ; 15: 505-508.
63. Martinelli V., Capra R., Cocco E., et al. High incidence of acute leukemia in multiple sclerosis patients treated with mitoxantrone: a retrospective multicentre Italian study. 25th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS). Sept 11, 2009. Poster 824.
64. Tullus K. and Marks SD Vasculitis in children and adolescents: clinical presentation, etiopathogenesis, and treatment. Paediatr Drugs 2009 ; 11: 375-380.
65. Makhani N., Gorman MP, Branson HM, et al. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology 2009 ; 72: 2076-2082.
66. Polman CH, Reingold SC, Barkhof F., et al. Ethics of placebo-controlled trials in multiple sclerosis: a reassessment. Neurology 2008 ; 70: 1134-1140.
67. Chabas D., Castello-Trivino T., Mowry EM, et al. Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype. Neurology 2008 ; 71: 1090-1109.
68. Waubant E., Chabas D., Okuda DT, et al. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol 2009 ; 66: 967-971.